These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 19283860

  • 21. Evaluation of the bioeffects of prenatal ultrasound exposure in the cynomolgus macaque (Macaca fascicularis): III. Developmental and hematologic studies.
    Tarantal AF, O'Brien WD, Hendrickx AG.
    Teratology; 1993 Feb; 47(2):159-70. PubMed ID: 8446929
    [Abstract] [Full Text] [Related]

  • 22. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice.
    Sugiura T, Kageyama S, Andou A, Miyazawa T, Ejima C, Nakayama A, Dohi T, Eda H.
    J Crohns Colitis; 2013 Dec; 7(11):e533-42. PubMed ID: 23623333
    [Abstract] [Full Text] [Related]

  • 23. Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
    Davenport RJ, Munday JR.
    Drug Discov Today; 2007 Jul; 12(13-14):569-76. PubMed ID: 17631252
    [Abstract] [Full Text] [Related]

  • 24. Developmental toxicity testing of monoclonal antibodies: an enhanced pre- and postnatal study design option.
    Stewart J.
    Reprod Toxicol; 2009 Sep; 28(2):220-5. PubMed ID: 19379807
    [Abstract] [Full Text] [Related]

  • 25. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of the bioeffects of prenatal ultrasound exposure in the cynomolgus macaque (Macaca fascicularis): II. Growth and behavior during the first year.
    Tarantal AF, Hendrickx AG.
    Teratology; 1989 Feb; 39(2):149-62. PubMed ID: 2648635
    [Abstract] [Full Text] [Related]

  • 27. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G, Rutgeerts P.
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [Abstract] [Full Text] [Related]

  • 28. Dietary zinc supplementation throughout pregnancy protects against fetal dysmorphology and improves postnatal survival after prenatal ethanol exposure in mice.
    Summers BL, Rofe AM, Coyle P.
    Alcohol Clin Exp Res; 2009 Apr; 33(4):591-600. PubMed ID: 19183140
    [Abstract] [Full Text] [Related]

  • 29. Natalizumab treatment during pregnancy - effects on the neonatal immune system.
    Schneider H, Weber CE, Hellwig K, Schroten H, Tenenbaum T.
    Acta Neurol Scand; 2013 Jan; 127(1):e1-4. PubMed ID: 22950358
    [Abstract] [Full Text] [Related]

  • 30. Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4.
    Shapiro RI, Plavina T, Schlain BR, Pepinsky RB, Garber EA, Jarpe M, Hochman PS, Wehner NG, Bard F, Motter R, Yednock TA, Taylor FR.
    J Pharm Biomed Anal; 2011 Apr 28; 55(1):168-75. PubMed ID: 21300512
    [Abstract] [Full Text] [Related]

  • 31. Adverse pregnancy outcome in the monkey (Macaca fascicularis) after chronic caffeine exposure.
    Gilbert SG, Rice DC, Reuhl KR, Stavric B.
    J Pharmacol Exp Ther; 1988 Jun 28; 245(3):1048-53. PubMed ID: 3385636
    [Abstract] [Full Text] [Related]

  • 32. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F, Carpani M, Chaudhary R, Ghosh S.
    Drugs; 2006 Jun 28; 66(9):1179-89. PubMed ID: 16827596
    [Abstract] [Full Text] [Related]

  • 33. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; 2006 Jun 28; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 34. Evidence for a regulatory role of alpha 4-integrins in the maturation of eosinophils generated from the bone marrow in the presence of dexamethasone.
    Gaspar-Elsas MI, Queto T, Vasconcelos Z, Jones CP, Lannes-Vieira J, Xavier-Elsas P.
    Clin Exp Allergy; 2009 Aug 28; 39(8):1187-98. PubMed ID: 19508325
    [Abstract] [Full Text] [Related]

  • 35. Use of barusiban in a novel study design for evaluation of tocolytic agents in pregnant and neonatal monkeys, including behavioural and immunological endpoints.
    Rasmussen AD, Nelson JK, Chellman GJ, Golub M, McAnulty PA.
    Reprod Toxicol; 2007 Jun 28; 23(4):471-9. PubMed ID: 17337159
    [Abstract] [Full Text] [Related]

  • 36. Cutting edge: Natalizumab blocks adhesion but not initial contact of human T cells to the blood-brain barrier in vivo in an animal model of multiple sclerosis.
    Coisne C, Mao W, Engelhardt B.
    J Immunol; 2009 May 15; 182(10):5909-13. PubMed ID: 19414741
    [Abstract] [Full Text] [Related]

  • 37. Spontaneous intracerebral hemorrhage in a patient with multiple sclerosis and tumefactive demyelinating lesion.
    Stich O, Janowitz D, Rauer S.
    Mult Scler; 2009 Apr 15; 15(4):517-9. PubMed ID: 19282415
    [Abstract] [Full Text] [Related]

  • 38. Natalizumab effects on immune cell responses in multiple sclerosis.
    Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, Trigueiro M, Racicot D, Guérette C, Antel JP, Fournier A, Grand'Maison F, Bar-Or A.
    Ann Neurol; 2006 May 15; 59(5):748-54. PubMed ID: 16634035
    [Abstract] [Full Text] [Related]

  • 39. Chronic administration of belatacept, a T-cell costimulatory signal blocker, in cynomolgus monkeys.
    Haggerty HG, Proctor SJ.
    Toxicol Sci; 2012 May 15; 127(1):159-68. PubMed ID: 22331490
    [Abstract] [Full Text] [Related]

  • 40. Prenatal endocrine activation alters postnatal cellular immunity in infant monkeys.
    Coe CL, Lubach GR, Karaszewski JW, Ershler WB.
    Brain Behav Immun; 1996 Sep 15; 10(3):221-34. PubMed ID: 8954595
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.